← Back to Clinical Trials
Recruiting NCT05380401

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

Trial Parameters

Condition Premature
Sponsor The University of Texas Health Science Center at San Antonio
Study Type INTERVENTIONAL
Phase N/A
Enrollment 328
Sex ALL
Min Age N/A
Max Age 36 Weeks
Start Date 2023-03-09
Completion 2027-04
Interventions
Enfamil® DHA & ARA Supplement for Special Dietary Use

Brief Summary

A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.

Eligibility Criteria

Inclusion Criteria: * born between 25 0/7 and 29 6/7 weeks of gestation * less than 48 hours of age at first lipid dose (The cohort is defined by gestational age rather than birth weight to avoid an over-represented sample of growth-restricted infants in birth weight defined cohorts.) Exclusion Criteria: * serious congenital anomalies * conditions at birth that will require surgery prior to discharge * imminent death such that withdrawal of intensive care support is anticipated within the first 72 hours after birth

Related Trials